Chengyi Biotechnology Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Shanghai China

Primary Industry

Biotechnology

About

Based in Shanghai, China and established in 2018, Chengyi Biotechnology is a pharmaceutical company that focuses on developing innovative small-molecule drugs. Jingye Zhou, the founder and CEO of the company, used to be the head of the chemical department of Lilly China R&D Center. In June 2023, the company raised CNY 180 million in series B funding co-led by new investors New Alliance Capital and Zhangjiang Venture. Other returning investors Delos Capital Partners, Oriza Holdings, Tsing Song Capital, new investors Elikon Venture, Golden China Fund, Rockbleu Capital, and Yufu Investment also participated in the round. The company's main products include low-dose small molecule GLP-1 receptor agonists, THR-β full agonists and SSAO/VAP-1 inhibitors, etc. Its products are used in metabolic and immune-related diseases. The company will use the series B funding for phase I clinical trials of small molecule GLP-1 receptor agonist ECC5004 for obesity and type 2 diabetes, and phase I clinical trials of THR-ß full agonist ECC4703 for NASH and lipid disorders.

Current Investors

Sinopharm Capital, MED-FINE Capital, TF Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.eccogene.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.